The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: II. BRCA1 and BRCA2
Abstract
OBJECTIVE: To provide recommendations for cancer surveillance and risk reduction for individuals carrying mutations in the BRCA1 or BRCA2 genes. PARTICIPANTS: A task force with expertise in medical genetics, oncology, primary care, gastroenterology, and epidemiology convened by the Cancer Genetics Studies Consortium (CGSC), organized by National Human Genome Research Institute (previously the National Center for Human Genome Research). EVIDENCE: Studies evaluating cancer risk, surveillance, and risk reduction in individuals genetically susceptible to breast and ovarian cancer were identified using MEDLINE (National Library of Medicine) and from bibliographies of articles thus identified. Indexing terms used were "genetics" in combination with "breast cancer," "ovarian cancer," and "screening," or "surveillance" in combination with "cancer family" and "BRCA1" and "BRCA2." For studies evaluating specific interventions, quality of evidence was assessed using criteria of the US Preventive Services Task Force. CONSENSUS PROCESS: The task force developed recommendations through discussions over a 14-month period. CONCLUSIONS: Efficacy of cancer surveillance or other measures to reduce risk in individuals who carry cancer-predisposing mutations is unknown. Based on expert opinion concerning presumptive benefit, early breast cancer and ovarian cancer screening are recommended for individuals with BRCA1 mutations and early breast cancer screening for those with BRCA2 mutations. No rec…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Five women in the BPM Group (19%) and 3 in the UPM group (7%) had previously undergone prophylactic oophorectomy (removal of the ovaries to try to prevent ovarian cancer) which is recommended for consideration by BRCA1/2 mutation carriers [Burke 1997]. Eighteen of the women in the COPM group (49%) had had a prophylactic oophorectomy.”
From Support needs and acceptability of psychological and peer consultation: Attitudes of 108 women who had undergone or were considering prophylactic mastectomy (2008) · cites this paper as Burke 1997
In the citing paper
“Prophylactic mastectomy (PM) is one of the few evidence-based, risk-reducing options open to female carriers of BRCA1/2 mutations [Burke 1997;] [Nelson 2005]”
From Support needs and acceptability of psychological and peer consultation: Attitudes of 108 women who had undergone or were considering prophylactic mastectomy (2008) · cites this paper as Burke 1997
Citations
Cites
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood
Mandel, J. S., Bond, J. H., Church, T. R., Snover, D. C., Bradley, G. M., Schuman, L. M., & Ederer, F. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305133281901 · Cited by 3,229
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D., Ettinger, B., Ernster, V. L., & Cummings, S. R. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-1016 · Cited by 2,336
Guide to Clinical Preventive Services
Wesley Allen, T. (1991) · The Journal of the American Osteopathic Association · doi:10.1515/jom-1991-900515 · Cited by 2,129
Localization of a Breast Cancer Susceptibility Gene, BRCA2 , to Chromosome 13q12-13
Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Averill, D., et al. (1994) · Science · doi:10.1126/science.8091231 · Cited by 1,924
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
A Case–Control Study of Screening Sigmoidoscopy and Mortality from Colorectal Cancer
Selby, J. V., Friedman, G. D., Quesenberry, C. P., & Weiss, N. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203053261001 · Cited by 1,702
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487
Cited by
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., Morris, E., Pisano, E., Schnall, M., Sener, S., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.2.75 · Cited by 2,637
Self-citationCannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Gene-Expression Profiles in Hereditary Breast Cancer
Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 1,733
American Cancer Society Guidelines for the Early Detection of Cancer
Smith, R. A., Cokkinides, V., von Eschenbach, A. C., Levin, B., Cohen, C., Runowicz, C. D., Sener, S., Saslow, D., & Eyre, H. J. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.1.8 · Cited by 1,588
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Metadata
- Authors
- Burke, W.
- Corresponding author
- Burke, Wylie
- ORCID
- Burke, Wylie
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1997-03-26
- Volume
- 277
- Issue
- 12
- Pages
- 997
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4236095073
- Cited by
- 955
- References
- 114
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 9 · 2021: 11 · 2020: 10 · 2019: 7 · 2018: 8 · 2017: 11 · 2016: 15 · 2015: 11 · 2014: 10 · 2013: 19 · 2012: 15
- FWCI
- 44.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- BRCA1, BRCA2, hereditary breast and ovarian cancer, cancer surveillance, cancer risk reduction, breast cancer screening, ovarian cancer screening, prophylactic surgery, cancer susceptibility
- MeSH terms
- Breast Neoplasms, Contraceptives, Oral, Decision Making, Disease Susceptibility, Female, Genetic Counseling, Genetic Markers, Genetic Testing, Heterozygote, Humans, Life Style, Male, Mammography, Mutation, Neoplasm Proteins, Neoplasms, Hormone-Dependent, Ovarian Neoplasms, Ovariectomy, Prostatic Neoplasms, Risk Factors, Transcription Factors, Colorectal Neoplasms, Estrogen Replacement Therapy, Breast Self-Examination, CA-125 Antigen, Ultrasonography, Doppler, Color, Antineoplastic Agents, Hormonal, Genes, BRCA1, BRCA2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: II. BRCA1 and BRCA2. https://app.cochat.ai/papers/10.1001/jama.277.12.997
- The paper
- Burke, W. (1997). Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: II. BRCA1 and BRCA2. JAMA. https://doi.org/10.1001/jama.277.12.997
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.